Anti-CD163 Antibody (OR2805)
Anti-CD163 Antibody (OR2805)
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | Antibody (OR2805) |
| Synonyms | Scavenger receptor cysteine-rich type 1 protein M130; Hemoglobin scavenger receptor; M130 |
| Location | Secreted, Cell membrane |
| Accession | Q86VB7 |
| Clone Number | OR2805 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | ELISA |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Background
OR2805 is a fully human IgG1 monoclonal antibody that targets CD163, an immune-suppressive receptor highly expressed on tumor-associated macrophages (TAMs) within the tumor microenvironment. This antibody was discovered using B cells from an elite responder to checkpoint inhibitor therapy. It has the potential to relieve immunosuppression caused by M2c macrophages, thereby enhancing anti-tumor T-cell responses. In preclinical studies, OR2805 demonstrated significant anti-tumor activity in lung cancer xenograft models and did not trigger the release of major cytokines in human whole blood. Currently, it is being evaluated in clinical trials as a potential cancer immunotherapy, both as a monotherapy and in combination with checkpoint inhibitors.
